MedTrace Logo

Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women

NCT03282799 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2024-09-05

Study results available
· View outcomes & findings →

Summary

This study will evaluate the frequency of ovulation and cervical mucus quality of HIV-infected Ugandan women on efavirenz-based antiretroviral therapy using either a single etonogestrel implant or two etonogestrel implants for at least one year.

Conditions

Interventions

DRUG

etonogestrel implant

The etonogestrel implant is an contraceptive implant that is placed into the upper arm.

Sponsors & Collaborators

  • Infectious Disease Institute, Kampala, Uganda

    collaborator OTHER

  • University of Nebraska

    collaborator OTHER

  • Catherine Anne Chappell

    lead OTHER

Principal Investigators

  • Catherine A Chappell, MD MSc · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-19
Primary Completion
2020-12-22
Completion
2022-10-25

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03282799 on ClinicalTrials.gov